• Exchange: Stockholm
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma


48.9000 SEK 0.8000 1.66%

As of 11:30:00 ET on 10/21/2014.

Snapshot for Probi AB (PROB)

Open: 46.6000 Day's Range: 46.6000 - 48.9000 Volume: 1,690
Previous Close: 48.1000 52wk Range: 37.0000 - 53.0000 1-Yr Rtn: +23.22%

Stock Chart for PROB

No chart data available.
  • PROB:SS 48.9000
  • 1D
  • 1M
  • 1Y
Interactive PROB Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PROB

Current P/E Ratio (ttm) 28.2721
Estimated P/E(12/2014) 25.0646
Relative P/E vs. OMX 1.9278
Earnings Per Share (SEK) (ttm) 1.7155
Est. EPS (SEK) (12/2014) 1.9350
Est. PEG Ratio -
Market Cap (M SEK) 454.22
Shares Outstanding (M) 9.37
30 Day Average Volume 5,053
Price/Book (mrq) 3.2464
Price/Sale (ttm) 4.1059
Dividend Indicated Gross Yield 1.55%
Cash Dividend (SEK) 0.7500
Dividend Ex-Date 04/30/2014
5 Year Dividend Growth -
Next Earnings Announcement 10/29/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PROB

  • Revenue
  • Net Income (M/SEK)
  • Profit Margin (%)

Company Profile & Key Executives for PROB

Probi AB carries out research and development in probiotics. The Company has three main research areas: surgery and medicine, foodstuff technology, and microbiology. Probi has developed the fruit drink ProViva, containing active bioculture intended to counteract harmful bacteria and strengthen the immune system. The Company also develops animal feed. Probi markets internationally.

Peter NaehlstedtChief Executive OfficerNiklas BrandtChief Financial Officer
Niklas BjaerumVP:Marketing & SalesGun Britt FranssonVP:Research&Development
More Company Profile & Key Executives for PROB

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil